+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Europe Novel Drug Delivery System (NDDS) Market - Growth, Trends, and Forecast (2019 - 2024)

  • ID: 4763909
  • Report
  • Region: Europe
  • 86 pages
  • Mordor Intelligence
until Dec 31st 2019
1 of 5


  • Abbott Laboratories
  • AstraZeneca PLC
  • Bayer AG
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Johnson & Johnson
  • MORE
Market Overview

The major factors that are driving growth in the European novel drug delivery system market are technological advancements promoting the development of NDDS and the rising need for controlled release of drugs.

Nowadays, for the treatment of chronic disorders as well as for controlling the release of active ingredients from drug products, a unique delivery system, the controlled release drug delivery system (CRDDS) of novel drug delivery, is included in the drug delivery technique. Majority of the active pharmaceutical ingredients are distributed in the form of CRDDS. A controlled drug delivery system is, thus, a very reliable, potential form of novel drug delivery technique, in which the drug is subjected to the appropriate pharmaceutical drug dosage form and its release is predetermined, making the release controlled at particular sites of action (cells, tissues, and organs).

Transdermal patches, implants, nasal systems, microcapsules, etc., are some of the common systems that are considered under controlled release systems. The need for controlled release of drugs is propelling the increasing demand for unique and innovative systems for drug delivery, where this novel drug delivery system plays a significant role in the advancement of controlled release of drugs, thereby driving the growth of the market, over the forecast period.

Scope of the Report

As per the scope of this report, novel drug delivery system refers to the approaches, technologies, systems, and formulations for transporting a pharmaceutical compound in the body as required to safely achieve its desired therapeutic effects. It is a novel system for the delivery of drugs, different from conventional drug delivery systems. The market is segmented by route of administration, mode of NDDS, and geography.

Key Market Trends

Targeted Drug Delivery Systems Segment under Mode of NDDS is Expected to hold the Largest Market Share during the Forecast Period

The targeted drug delivery system segment is expected to hold the largest share in the market owing to the benefits associated with it. Targeted drug delivery is a mixture of controlled drug delivery and sustained drug delivery systems. This method of administration of drugs assures greater efficacy, owing to the higher concentration of the drug at the target area in the body.

In the targeted drug delivery system, the drug, which is released at the site of action, then gets attached to the diseased tissue. One of the prime benefits of this mode of drug delivery is controlled and protected action, as the slow, prolonged action of the drug on the diseased tissue for an adequate period of treatment time is expected to provide potential benefits. These benefits of targeted drug delivery, coupled with the increasing need for technological advancements and a rising need for higher efficacy, owing to the increasing burden of chronic diseases, are propelling the growth of the segment.

Competitive Landscape

The market comprises major market players who are primarily focused on research and development for the creation of a stable and safe formulation. The market has been experiencing technological developments on a large scale for the past couple of years. Some of the market players are Abbott Laboratories, AstraZeneca PLC, Bayer AG, GlaxoSmithKline PLC, Novartis AG, Pfizer Inc., F. Hoffmann-La Roche AG, and Sanofi SA.
Note: Product cover images may vary from those shown
2 of 5


  • Abbott Laboratories
  • AstraZeneca PLC
  • Bayer AG
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Johnson & Johnson
  • MORE
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study



4.1 Market Overview
4.2 Market Drivers
4.2.1 Technological Advancements Promoting the Development of NDDS
4.2.2 Rising Need for the Controlled Release of Drugs
4.3 Market Restraints
4.3.1 Stringent Regulatory Guidelines
4.3.2 Stability Issues
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5.1 By Route of Administration
5.1.1 Oral Drug Delivery Systems
5.1.2 Injectable Drug Delivery Systems
5.1.3 Pulmonary Drug Delivery Systems
5.1.4 Transdermal Drug Delivery Systems
5.1.5 Other Routes of Administration
5.2 By Mode of NDDS
5.2.1 Targeted Drug Delivery Systems
5.2.2 Controlled Drug Delivery Systems
5.2.3 Modulated Drug Delivery Systems
5.3 Geography
5.3.1 Europe United Kingdom Germany France Italy Spain Rest of Europe

6.1 Company Profiles
6.1.1 Abbott Laboratories
6.1.2 AstraZeneca PLC
6.1.3 Bayer AG
6.1.4 GlaxoSmithKline PLC
6.1.5 Johnson & Johnson
6.1.6 Merck & Co. Inc.
6.1.7 Novartis AG
6.1.8 Pfizer Inc.
6.1.9 F. Hoffmann-La Roche AG
6.1.10 Sanofi SA

Note: Product cover images may vary from those shown
3 of 5


4 of 5
  • Abbott Laboratories
  • AstraZeneca PLC
  • Bayer AG
  • GlaxoSmithKline PLC
  • Johnson & Johnson
  • Merck & Co. Inc.
  • Novartis AG
  • Pfizer Inc.
  • F. Hoffmann-La Roche AG
  • Sanofi SA
Note: Product cover images may vary from those shown
5 of 5